The updated labeling provides a new conversion chart for starting dosages when switching patients from subcutaneous mealtime #insulin to #Afrezza.
Read More: https://bit.ly/4byiEur
0
0
0
0
The updated labeling provides a new conversion chart for starting dosages when switching patients from subcutaneous mealtime #insulin to #Afrezza.
Read More: https://bit.ly/4byiEur
If you missed it:
Today, the FDA accepted MannKind Corporation's sBLA for #Afrezza Inhalation Powder to include children and adolescents with type 1 or type 2 #diabetes.
READ MORE:
www.contemporarypediatrics.com/view/fda-acc...
Inhaled Insulin Emerges as a Viable Option for Managing Type 1 Diabetes in Children #United_States #Chicago #Type_1_Diabetes #Inhaled_Insulin #Afrezza